Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib
Human hepatocellular carcinoma (HCC) is the most frequent primary tumor of the liver and the third cause of cancer-related deaths. The multikinase inhibitor sorafenib is a systemic drug for unresectable HCC. The identification of molecular biomarkers for the early diagnosis of HCC and responsiveness...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/9/7/813 |
| _version_ | 1797527600774512640 |
|---|---|
| author | Michele Manganelli Ilaria Grossi Manuela Ferracin Paola Guerriero Massimo Negrini Michele Ghidini Chiara Senti Margherita Ratti Claudio Pizzo Rodolfo Passalacqua Sarah Molfino Gianluca Baiocchi Nazario Portolani Eleonora Marchina Giuseppina De Petro Alessandro Salvi |
| author_facet | Michele Manganelli Ilaria Grossi Manuela Ferracin Paola Guerriero Massimo Negrini Michele Ghidini Chiara Senti Margherita Ratti Claudio Pizzo Rodolfo Passalacqua Sarah Molfino Gianluca Baiocchi Nazario Portolani Eleonora Marchina Giuseppina De Petro Alessandro Salvi |
| author_sort | Michele Manganelli |
| collection | DOAJ |
| description | Human hepatocellular carcinoma (HCC) is the most frequent primary tumor of the liver and the third cause of cancer-related deaths. The multikinase inhibitor sorafenib is a systemic drug for unresectable HCC. The identification of molecular biomarkers for the early diagnosis of HCC and responsiveness to treatment are needed. In this work, we performed an exploratory study to investigate the longitudinal levels of cell-free long ncRNA GAS5 and microRNAs miR-126-3p and -23b-3p in a cohort of 7 patients during the period of treatment with sorafenib. We used qPCR to measure the amounts of GAS5 and miR-126-3p and droplet digital PCR (ddPCR) to measure the levels of miR-23b-3p. Patients treated with sorafenib displayed variable levels of GAS5, miR-126-3p and miR-23b-3p at different time-points of follow-up. miR-23b-3p was further measured by ddPCR in 37 healthy individuals and 25 untreated HCC patients. The amount of miR-23b-3p in the plasma of untreated HCC patients was significantly downregulated if compared to healthy individuals. The ROC curve analysis underlined its diagnostic relevance. In conclusion, our results highlight a potential clinical significance of circulating miR-23b-3p and an exploratory observation on the longitudinal plasmatic levels of GAS5, miR-126-3p and miR-23b-3p during sorafenib treatment. |
| first_indexed | 2024-03-10T09:45:08Z |
| format | Article |
| id | doaj.art-84fb4fbdb40a4d67baf615514974a709 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T09:45:08Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-84fb4fbdb40a4d67baf615514974a7092023-11-22T03:17:25ZengMDPI AGBiomedicines2227-90592021-07-019781310.3390/biomedicines9070813Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with SorafenibMichele Manganelli0Ilaria Grossi1Manuela Ferracin2Paola Guerriero3Massimo Negrini4Michele Ghidini5Chiara Senti6Margherita Ratti7Claudio Pizzo8Rodolfo Passalacqua9Sarah Molfino10Gianluca Baiocchi11Nazario Portolani12Eleonora Marchina13Giuseppina De Petro14Alessandro Salvi15Department of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, 25123 Brescia, ItalyDepartment of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, 25123 Brescia, ItalyDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40126 Bologna, ItalyDepartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, 44121 Ferrara, ItalyDepartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, 44121 Ferrara, ItalyDepartment of Oncology, Azienda Socio Sanitaria Territoriale of Cremona, 26100 Cremona, ItalyDepartment of Oncology, Azienda Socio Sanitaria Territoriale of Cremona, 26100 Cremona, ItalyDepartment of Oncology, Azienda Socio Sanitaria Territoriale of Cremona, 26100 Cremona, ItalyDepartment of Oncology, Azienda Socio Sanitaria Territoriale of Cremona, 26100 Cremona, ItalyDepartment of Oncology, Azienda Socio Sanitaria Territoriale of Cremona, 26100 Cremona, ItalyDepartment of Clinical and Experimental Sciences, Surgical Clinic, University of Brescia, 25123 Brescia, ItalyDepartment of Clinical and Experimental Sciences, Surgical Clinic, University of Brescia, 25123 Brescia, ItalyDepartment of Clinical and Experimental Sciences, Surgical Clinic, University of Brescia, 25123 Brescia, ItalyDepartment of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, 25123 Brescia, ItalyDepartment of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, 25123 Brescia, ItalyDepartment of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, 25123 Brescia, ItalyHuman hepatocellular carcinoma (HCC) is the most frequent primary tumor of the liver and the third cause of cancer-related deaths. The multikinase inhibitor sorafenib is a systemic drug for unresectable HCC. The identification of molecular biomarkers for the early diagnosis of HCC and responsiveness to treatment are needed. In this work, we performed an exploratory study to investigate the longitudinal levels of cell-free long ncRNA GAS5 and microRNAs miR-126-3p and -23b-3p in a cohort of 7 patients during the period of treatment with sorafenib. We used qPCR to measure the amounts of GAS5 and miR-126-3p and droplet digital PCR (ddPCR) to measure the levels of miR-23b-3p. Patients treated with sorafenib displayed variable levels of GAS5, miR-126-3p and miR-23b-3p at different time-points of follow-up. miR-23b-3p was further measured by ddPCR in 37 healthy individuals and 25 untreated HCC patients. The amount of miR-23b-3p in the plasma of untreated HCC patients was significantly downregulated if compared to healthy individuals. The ROC curve analysis underlined its diagnostic relevance. In conclusion, our results highlight a potential clinical significance of circulating miR-23b-3p and an exploratory observation on the longitudinal plasmatic levels of GAS5, miR-126-3p and miR-23b-3p during sorafenib treatment.https://www.mdpi.com/2227-9059/9/7/813HCCsorafenibddPCRGAS5miR-126-3pmiR-23b-3p |
| spellingShingle | Michele Manganelli Ilaria Grossi Manuela Ferracin Paola Guerriero Massimo Negrini Michele Ghidini Chiara Senti Margherita Ratti Claudio Pizzo Rodolfo Passalacqua Sarah Molfino Gianluca Baiocchi Nazario Portolani Eleonora Marchina Giuseppina De Petro Alessandro Salvi Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib Biomedicines HCC sorafenib ddPCR GAS5 miR-126-3p miR-23b-3p |
| title | Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib |
| title_full | Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib |
| title_fullStr | Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib |
| title_full_unstemmed | Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib |
| title_short | Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib |
| title_sort | longitudinal circulating levels of mir 23b 3p mir 126 3p and lncrna gas5 in hcc patients treated with sorafenib |
| topic | HCC sorafenib ddPCR GAS5 miR-126-3p miR-23b-3p |
| url | https://www.mdpi.com/2227-9059/9/7/813 |
| work_keys_str_mv | AT michelemanganelli longitudinalcirculatinglevelsofmir23b3pmir1263pandlncrnagas5inhccpatientstreatedwithsorafenib AT ilariagrossi longitudinalcirculatinglevelsofmir23b3pmir1263pandlncrnagas5inhccpatientstreatedwithsorafenib AT manuelaferracin longitudinalcirculatinglevelsofmir23b3pmir1263pandlncrnagas5inhccpatientstreatedwithsorafenib AT paolaguerriero longitudinalcirculatinglevelsofmir23b3pmir1263pandlncrnagas5inhccpatientstreatedwithsorafenib AT massimonegrini longitudinalcirculatinglevelsofmir23b3pmir1263pandlncrnagas5inhccpatientstreatedwithsorafenib AT micheleghidini longitudinalcirculatinglevelsofmir23b3pmir1263pandlncrnagas5inhccpatientstreatedwithsorafenib AT chiarasenti longitudinalcirculatinglevelsofmir23b3pmir1263pandlncrnagas5inhccpatientstreatedwithsorafenib AT margheritaratti longitudinalcirculatinglevelsofmir23b3pmir1263pandlncrnagas5inhccpatientstreatedwithsorafenib AT claudiopizzo longitudinalcirculatinglevelsofmir23b3pmir1263pandlncrnagas5inhccpatientstreatedwithsorafenib AT rodolfopassalacqua longitudinalcirculatinglevelsofmir23b3pmir1263pandlncrnagas5inhccpatientstreatedwithsorafenib AT sarahmolfino longitudinalcirculatinglevelsofmir23b3pmir1263pandlncrnagas5inhccpatientstreatedwithsorafenib AT gianlucabaiocchi longitudinalcirculatinglevelsofmir23b3pmir1263pandlncrnagas5inhccpatientstreatedwithsorafenib AT nazarioportolani longitudinalcirculatinglevelsofmir23b3pmir1263pandlncrnagas5inhccpatientstreatedwithsorafenib AT eleonoramarchina longitudinalcirculatinglevelsofmir23b3pmir1263pandlncrnagas5inhccpatientstreatedwithsorafenib AT giuseppinadepetro longitudinalcirculatinglevelsofmir23b3pmir1263pandlncrnagas5inhccpatientstreatedwithsorafenib AT alessandrosalvi longitudinalcirculatinglevelsofmir23b3pmir1263pandlncrnagas5inhccpatientstreatedwithsorafenib |